US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...